Italia markets close in 6 hours 40 minutes

Celularity Inc. (CELU)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
4,9400-0,0900 (-1,79%)
Alla chiusura: 04:00PM EDT
4,7700 -0,17 (-3,44%)
Dopo ore: 04:41PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente5,0300
Aperto5,0700
Denaro4,7400 x 100
Lettera5,1100 x 100
Min-Max giorno4,7500 - 5,0999
Intervallo di 52 settimane1,5900 - 8,9000
Volume32.541
Media Volume280.907
Capitalizzazione107,608M
Beta (5 anni mensile)0,24
Rapporto PE (ttm)N/D
EPS (ttm)-10,3000
Prossima data utili29 mar 2024 - 02 apr 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors

    Pharmaceutical and Academic Veteran Brings Significant Innovative Technology and Development Expertise Launching New Cellular TherapiesFLORHAM PARK, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies and advanced biomaterial products, today announced the appointment of Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors. Dr. Ling, a distinguished academic and

  • GlobeNewswire

    Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron

    Celularity to provide research support for Regeneron's targeted, allogeneic, chimeric antigen receptor (CAR) T-cell therapyAgreement underscores Celularity's demonstrated expertise in cell therapy research FLORHAM PARK, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing allogeneic cell therapies and biomaterial products, announced today a multi-year Research Collaboration Services Agreement with Regeneron Pharmaceuticals, Inc.

  • GlobeNewswire

    Celularity Inc. Announces $3 Million Registered Direct Offering

    FLORHAM PARK, N.J., July 27, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it has entered into a definitive agreement with a single, healthcare-focused institutional investor for the purchase and sale of 8,571,428 shares of its Class A common stock together with warrants to purchase up to 8,571,428 shares of its Class A common stock at a combined